Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - Non-metastatic NSCLC and other thoracic malignancies

LBA61 - Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

Date

18 Sep 2021

Session

Mini oral session - Non-metastatic NSCLC and other thoracic malignancies

Topics

Immunotherapy

Tumour Site

Small Cell Lung Cancer

Presenters

Luis Paz-Ares

Citation

Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741

Authors

L. Paz-Ares1, Y. Chen2, N. Reinmuth3, K. Hotta4, D. Trukhin5, G. Statsenko6, M.J. Hochmair7, M. Ozguroglu8, J.H. Ji9, O. Voitko10, A. Poltoratskiy11, F. Verderame12, L. Havel13, I. Bondarenko14, G. Losonczy15, N.V. Conev16, H.L. Broadhurst17, T. Dalvi18, H. Jiang19, J.W. Goldman20

Author affiliations

  • 1 Medical Oncology Department, Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Clinical Research Unit, Universidad Complutense & Ciberonc, 28041 - Madrid/ES
  • 2 Oncology Department, Cancer & Hematology Centers of Western Michigan, Grand Rapids/US
  • 3 Thoracic Oncology Department, Asklepios Lung Clinic, 82131 - Munich-Gauting/DE
  • 4 Center For Innovative Clinical Medicine, Okayama University Hospital, 700-8558 - Okayama/JP
  • 5 Outpatient Chemotherapy, Odessa Regional Oncological Dispensary, 65000 - Odessa/UA
  • 6 Ministry Of Health, Omsk Regional Cancer Center, 644086 - Omsk/RU
  • 7 Respiratory Oncology Unit, Department Of Respiratory And Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, A-1210 - Vienna/AT
  • 8 Cerrahpaşa School Of Medicine, Istanbul University−Cerrahpaşa, 34096 - Istanbul/TR
  • 9 Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 630-723 - Changwon/KR
  • 10 Thoracic Surgery, Kyiv City Clinical Oncological Centre, 03142 - Kiev/UA
  • 11 Department Of Clinical Trials, N.N. Petrov National Medical Research Center of Oncology, St Petersburg/RU
  • 12 Medical Oncology, AO Ospedali Riuniti PO Vincenzo Cervello, Palermo/IT
  • 13 Thomayer Hospital, First Faculty Of Medicine, Charles University, 14059 - Prague/CZ
  • 14 Oncology And Medical Radiology, Dnipropetrovsk Medical Academy, 49102 - Dnipro/UA
  • 15 Department Of Pulmonology, Semmelweis University, 1083 - Budapest/HU
  • 16 Clinic Of Medical Oncology, UMHAT St Marina, 9000 - Varna/BG
  • 17 Statistics, Plus-Project Ltd, WA16 8GS - Alderley Park/GB
  • 18 Late Oncology R&d, AstraZeneca, 20878 - Gaithersburg/US
  • 19 Clinical Development, Oncology R&d, AstraZeneca, 20878 - Gaithersburg/US
  • 20 Department Of Medicine, David Geffen School of Medicine at UCLA, 90095 - Los Angeles/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract LBA61

Background

In CASPIAN, the Phase 3 study of etoposide + cisplatin/carboplatin (EP) ± durvalumab (D) ± tremelimumab (T) as first-line treatment of ES-SCLC, D + EP demonstrated a statistically significant improvement in OS vs EP alone (data cut-off [DCO]: 11 Mar 2019; HR 0.73 [95% CI 0.59–0.91; p=0.0047]). In a subsequent analysis after a median follow-up of 25.1 mo (DCO 27 Jan 2020), OS benefit with D + EP vs EP was sustained (HR 0.75 [95% CI 0.62–0.91; nominal p=0.0032]), and D + T + EP numerically improved OS vs EP (HR 0.82 [95% CI 0.68–1.00; p=0.0451]), but did not reach statistical significance (p≤0.0418). Here we report updated OS after a median follow-up of >3 years, the longest reported to date for a phase 3 trial of EP + PD(L)1 in this disease setting.

Methods

Pts with treatment-naïve ES-SCLC were randomised 1:1:1 to D 1500 mg + EP q3w, D 1500 mg + T 75 mg + EP q3w, or EP q3w. Pts in the IO arms received 4 cycles of EP + D ± T, followed by maintenance D 1500 mg q4w. Pts in the EP arm received up to 6 cycles of EP. The two primary endpoints were OS for D + EP vs EP and for D + T + EP vs EP. Serious AEs (SAEs) were assessed during long-term follow up.

Results

268, 268 and 269 pts were randomized to D + EP, D + T + EP and EP, respectively. At a DCO of 27 Mar 2021, median follow-up was 39.4 mo, 86% maturity. D + EP continued to demonstrate improved OS vs EP: HR 0.71 (95% CI 0.60–0.86; nominal p=0.0003). Median OS was 12.9 vs 10.5 mo; 22.9% vs 13.9% of pts were alive at 24 mo; and 17.6% vs 5.8% of pts were alive at 36 mo with D + EP vs EP, respectively. D + T + EP continued to numerically improve OS vs EP: HR 0.81 (95% CI 0.67–0.97; nominal p=0.02); median OS was 10.4 mo, and 15.3% of pts were alive at 36 mo. 46 pts remained on treatment with D at DCO (27 in the D + EP arm and 19 in the D + T + EP arm). In D + EP, D + T + EP and EP arms, respectively, incidences of SAEs (all cause) were 32.5%, 47.4% and 36.5%; and AEs leading to death (all cause) were 5.3%, 10.9% and 6.0%.

Conclusions

D + EP demonstrated sustained OS benefit over EP with a well-tolerated safety profile after >3 years of median follow-up, consistent with previous analyses. 3 times more pts were estimated to be alive at 3 years when treated with D + EP vs EP alone, further establishing D + EP as standard of care for first-line treatment of ES-SCLC.

Clinical trial identification

NCT03043872 (release date: February 6, 2017).

Editorial acknowledgement

Medical writing support for the development of this abstract, under the direction of the authors, was provided by Helen Kitchen of Ashfield MedComms (Macclesfield, UK), an Ashfield Health company, and was funded by AstraZeneca.

Legal entity responsible for the study

AstraZeneca PLC.

Funding

AstraZeneca.

Disclosure

L. Paz-Ares: Financial Interests, Personal, Leadership Role: Genomica, Altum Sequencing; Financial Interests, Personal, Other, Personal fees [travel, accommodation, other expenses]: Roche, AstraZeneca, AstraZeneca Spain, Merck Sharp and Dohme, Bristol Myers Squibb, Lilly, Pfizer; Financial Interests, Personal, Other, Honoraria: Roche, Genentech, Lilly, Pfizer, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp and Dohme, AstraZeneca, Merck Serono, PharmaMar, Novartis, Celgene, Sysmex, Bayer, Amgen, Blueprint Medicines, Incyte; Financial Interests, Personal, Other, Fees (immediate family member): Novartis, Ipsen, Pfizer, Servier, Sanofi, Roche, Amgen, Merck. Y. Chen: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Writing Engagements: AstraZeneca, IPSEN; Financial Interests, Personal and Institutional, Principal Investigator: AstraZeneca, IPSEN, EMD Serono; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Bristol Myers Squibb, Merck, Guardant Health, Pfizer, Jazz Pharmaceuticals, Takeda; Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Myers Squibb, Merck, IPSEN, Jazz Pharmaceuticals. N. Reinmuth: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Hoffmann-La Roche, MSD, Merck, Pfizer, Takeda; Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Hoffmann-La Roche, MSD, Merck, Pfizer, Takeda; Financial Interests, Personal and Institutional, Principal Investigator: Amgen, AstraZeneca, Beigene, BMS, Daiichi Sankyo, IO Biotech, Janssen-cilag International NV, Jiangsu Hengrui Medicine, Lilly, Merck, Merck Sharp & Dohme Corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda. K. Hotta: Financial Interests, Personal, Speaker’s Bureau: Pfizer, AstraZeneca, Chugai, Lilly, Takeda, MSD, BMS, Ono, NipponKayaku, Taiho, Boehringer Ingelheim; Financial Interests, Personal and Institutional, Research Grant: MSD, AstraZeneca, Chugai, Lilly, BMS. M.J. Hochmair: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Roche, Boehringer Ingelheim, Takeda, Lilly; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, MSD, Roche, Boehringer Ingelheim, Takeda, Lilly; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Roche, Boehringer Ingelheim, Takeda, Lilly. J.H. Ji: Non-Financial Interests, Personal, Invited Speaker: LG life Sciences; Non-Financial Interests, Personal, Advisory Board: HK inno.N; Non-Financial Interests, Personal and Institutional, Principal Investigator: AstraZeneca, Roche, Hyndai Pharm, Celltrion, Boryung Pharm. I. Bondarenko: Financial Interests, Personal and Institutional, Principal Investigator: Amgen, AstraZeneca, BMS, Lilly, Merck Sharp & Dohme Corp, Novartis, Pfizer, Roche, Sanofi, Takeda, Tesaro. H.L. Broadhurst: Financial Interests, Personal, Full or part-time Employment, Contracted to AastraZeneca: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. T. Dalvi: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. H. Jiang: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. J.W. Goldman: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, BMS, Genentech, Janssen, Pfizer; Non-Financial Interests, Personal and Institutional, Research Grant: AbbVie, Advaxis, Array/Pfizer, AstraZeneca, BMS, Eli Lilly, Genentech, Merck, Pfizer, Puma, Spectrum, Tesaro, Vaccinex; Non-Financial Interests, Personal and Institutional, Principal Investigator: AbbVie, Advaxis, Array/Pfizer, AstraZeneca, BMS, Eli Lilly, Genentech, Merck, Pfizer, Puma, Spectrum, Tesaro, Vaccinex. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.